Home

Vindobona journal of international commercial law and arbitration (Vienna) 9:2:219-221, 2005. (...) Vindobona journal of international commercial law and arbitration (Vienna) 9:2:223-231, 2005. (...) Vindobona journal of international commercial law and arbitration (Vienna) 9:2:303-311, 2005.

Dalhuisen on transnational comparative, commercial, financial and trade law, Volume 2: contract and movable property law. 6th ed. (...) Software transactions in transnational commercial law. George Mason journal of international commercial law (Arlington, Va.) 7:3: 184–201, 2016. (...) Dalhuisen on transnational comparative, commercial, financial and trade law, Volume 1: the transnationalisation of commercial and financial law and of commercial, financial and investment dispute resolution.

Shaluka Ediriweera Commercial Officer Permanent Mission Sweden Representatives: Ms. (...) Palmieri Former Chairman Commercial Finance Association (CFA) New York, New York Mr. (...) Cove Deputy Executive Director Commercial Finance Association (CFA) New York, New York Forum for International Commercial Arbitration Representatives: Mr.

Heidemann, M. International commercial harmonisation and national resistance: the development and reform of transnational commercial law and its application within national legal culture. (...) Stockholm, Stockholm Centre for Commercial Law, Juridiska institutionen, 2009. 150 p. (...) Lloyd’s maritime and commercial law quarterly (London) 2:201-207, May 2010.

The right to health must be consistently integrated across all relevant policies, programmes and projects of a pharmaceutical company, including those relating to pricing, intellectual property, research and development, clinical trials, and marketing. (...) When endeavouring to make the medicine as accessible as possible to all those in need, the company must use all the arrangements at its disposal, including differential pricing between countries, differential pricing within countries (e.g. market segmentation), non-exclusive commercial voluntary licences, non-commercial voluntary licences, donation programmes, public-private partnerships, and so on. 39. (...) According to the pharmaceutical companies the Act, which provided for compulsory licensing, parallel importation and other TRIPS ‘flexibilities’, undermined intellectual property rights. The case generated fierce criticism of the pharmaceutical industry and was eventually the subject of an out-of-court settlement.

Maria TZOKOVA Solomon Pearl Blum Heymann & Stich LLP New York, New York COMMERCIAL FINANCE ASSOCIATION (CFA) Representatives: Mr. (...) Deputy Executive Director, Commercial Finance Association (CFA) New York, New York FORUM FOR INTERNATIONAL COMMERCIAL ARBITRATION (FICA) Representatives: Mr. (...) Koula HATZIKIRIAKOS Expert in Intellectual Property Issues INTERNATIONAL TRADEMARK ASSOCIATION (INTA) Representatives: Mr.

The rules require them to submit: (1) a statement of general liquidation of the company’s human and material resources, with a report to the Ministry of Security; (2) a certificate of solvency issued by the country’s tax authorities; and (3) a certificate of liquidation issued by the Property Institute (formerly the Property Registry). (...) Their wages are paid by the companies and they cannot work for third parties in return for remuneration as their activities are carried out on the grounds or premises of the property of the individual or legal entity hiring them. (...) With reference to the organization of security corps for businesses, these simply carry out guard duties on those parts of the business property that are used exclusively by the owner.

The right to health must be consistently integrated across all relevant policies, programmes and projects of a pharmaceutical company, including those relating to pricing, intellectual property, research and development, clinical trials, and marketing. (...) When endeavouring to make the medicine as accessible as possible to all those in need, the company must use all the arrangements at its disposal, including differential pricing between countries, differential pricing within countries (e.g. market segmentation), non-exclusive commercial voluntary licences, non-commercial voluntary licences, donation programmes, public-private partnerships, and so on. 39. (...) According to the pharmaceutical companies the Act, which provided for compulsory licensing, parallel importation and other TRIPS ‘flexibilities’, undermined intellectual property rights. The case generated fierce criticism of the pharmaceutical industry and was eventually the subject of an out-of-court settlement.

Alexander KOMAROV President, International Commercial Arbitration Court Chamber of Commerce and Industry Mr. (...) WORLD INTERNATIONAL PROPERTY ORGANIZATION (WIPO) Representative: Mr. (...) LADISLAW Solomon Pearl Blum Heymann & Stich LLP FORUM FOR INTERNATIONAL COMMERCIAL ARBITRATION (FICA) Representative: Mr.

Recognizing and preventing commercial fraud: indicators of commercial fraud, prepared by the UNCITRAL secretariat. (...) A/CN.9/805 V.14-02394 5 Bilotta, C. Ending the commercial siesta: the shortcomings of European Union Directive 2011/7 on combating late payments in commercial transactions. (...) Kayibanda, R. Passing of property in goods in contracts of international sale of goods.